Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Kristensen, JM, Lillelund, C, Kjøbsted, R, Birk, JB, Andersen, NR, Nybo, L, Mellberg, K, Balendran, A, Richter, EA & Wojtaszewski, JFP 2019, 'Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial', Physiological Reports, bind 7, nr. 23, e14307, s. 1-17. https://doi.org/10.14814/phy2.14307

APA

Kristensen, J. M., Lillelund, C., Kjøbsted, R., Birk, J. B., Andersen, N. R., Nybo, L., Mellberg, K., Balendran, A., Richter, E. A., & Wojtaszewski, J. F. P. (2019). Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial. Physiological Reports, 7(23), 1-17. [e14307]. https://doi.org/10.14814/phy2.14307

CBE

Kristensen JM, Lillelund C, Kjøbsted R, Birk JB, Andersen NR, Nybo L, Mellberg K, Balendran A, Richter EA, Wojtaszewski JFP. 2019. Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial. Physiological Reports. 7(23):1-17. https://doi.org/10.14814/phy2.14307

MLA

Vancouver

Author

Kristensen, Jonas M ; Lillelund, Christian ; Kjøbsted, Rasmus ; Birk, Jesper B ; Andersen, Nicoline R ; Nybo, Lars ; Mellberg, Karin ; Balendran, Anudharan ; Richter, Erik A ; Wojtaszewski, Jørgen F P. / Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise : A randomised, crossover trial. I: Physiological Reports. 2019 ; Bind 7, Nr. 23. s. 1-17.

Bibtex

@article{fcf34178298843739586b1f512c35dc9,
title = "Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial",
abstract = "5´AMP-activated protein kinase (AMPK) is a mediator of a healthy metabolic phenotype in skeletal muscle. Metformin may exacerbate the energy disturbances observed during exercise leading to enhanced AMPK activation, and these disturbances may provoke early muscular fatigue. We studied acute (1 day) and short-term (4 days) effects of metformin treatment on AMPK and its downstream signaling network, in healthy human skeletal muscle and adipose tissue at rest and during exercise, by applying a randomized blinded crossover study design in 10 lean men. Muscle and fat biopsies were obtained before and after the treatment period at rest and after a single bout of exercise. Metformin treat ment elicited peak plasma and muscle metformin concentrations of 31 μM and 11 μM, respectively. Neither of the treatments affected AMPK activity in skeletal muscle and adipose at rest or during exercise. In contrast, whole-body stress during exercise was elevated as indicated by increased plasma lactate and adrenaline concentrations as well as increased heart rate and rate of perceived exertion. Also whole-body insulin sensitivity was enhanced by 4 days metformin treatment, that is reduced fasting plasma insulin and HOMA-IR. In conclusion, acute and short-term metformin treatment does not affect energy homeostasis and AMPK activation at rest or during exercise in skeletal muscle and adipose tissue of healthy subjects. However, metformin treatment is accompanied by slightly enhanced perceived exertion and whole-body stress which may provoke a lesser desire for physical activity in the metformin-treated patients.",
author = "Kristensen, {Jonas M} and Christian Lillelund and Rasmus Kj{\o}bsted and Birk, {Jesper B} and Andersen, {Nicoline R} and Lars Nybo and Karin Mellberg and Anudharan Balendran and Richter, {Erik A} and Wojtaszewski, {J{\o}rgen F P}",
note = "{\textcopyright} 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.",
year = "2019",
month = dec,
doi = "10.14814/phy2.14307",
language = "English",
volume = "7",
pages = "1--17",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "Wiley Periodicals, Inc.",
number = "23",

}

RIS

TY - JOUR

T1 - Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise

T2 - A randomised, crossover trial

AU - Kristensen, Jonas M

AU - Lillelund, Christian

AU - Kjøbsted, Rasmus

AU - Birk, Jesper B

AU - Andersen, Nicoline R

AU - Nybo, Lars

AU - Mellberg, Karin

AU - Balendran, Anudharan

AU - Richter, Erik A

AU - Wojtaszewski, Jørgen F P

N1 - © 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.

PY - 2019/12

Y1 - 2019/12

N2 - 5´AMP-activated protein kinase (AMPK) is a mediator of a healthy metabolic phenotype in skeletal muscle. Metformin may exacerbate the energy disturbances observed during exercise leading to enhanced AMPK activation, and these disturbances may provoke early muscular fatigue. We studied acute (1 day) and short-term (4 days) effects of metformin treatment on AMPK and its downstream signaling network, in healthy human skeletal muscle and adipose tissue at rest and during exercise, by applying a randomized blinded crossover study design in 10 lean men. Muscle and fat biopsies were obtained before and after the treatment period at rest and after a single bout of exercise. Metformin treat ment elicited peak plasma and muscle metformin concentrations of 31 μM and 11 μM, respectively. Neither of the treatments affected AMPK activity in skeletal muscle and adipose at rest or during exercise. In contrast, whole-body stress during exercise was elevated as indicated by increased plasma lactate and adrenaline concentrations as well as increased heart rate and rate of perceived exertion. Also whole-body insulin sensitivity was enhanced by 4 days metformin treatment, that is reduced fasting plasma insulin and HOMA-IR. In conclusion, acute and short-term metformin treatment does not affect energy homeostasis and AMPK activation at rest or during exercise in skeletal muscle and adipose tissue of healthy subjects. However, metformin treatment is accompanied by slightly enhanced perceived exertion and whole-body stress which may provoke a lesser desire for physical activity in the metformin-treated patients.

AB - 5´AMP-activated protein kinase (AMPK) is a mediator of a healthy metabolic phenotype in skeletal muscle. Metformin may exacerbate the energy disturbances observed during exercise leading to enhanced AMPK activation, and these disturbances may provoke early muscular fatigue. We studied acute (1 day) and short-term (4 days) effects of metformin treatment on AMPK and its downstream signaling network, in healthy human skeletal muscle and adipose tissue at rest and during exercise, by applying a randomized blinded crossover study design in 10 lean men. Muscle and fat biopsies were obtained before and after the treatment period at rest and after a single bout of exercise. Metformin treat ment elicited peak plasma and muscle metformin concentrations of 31 μM and 11 μM, respectively. Neither of the treatments affected AMPK activity in skeletal muscle and adipose at rest or during exercise. In contrast, whole-body stress during exercise was elevated as indicated by increased plasma lactate and adrenaline concentrations as well as increased heart rate and rate of perceived exertion. Also whole-body insulin sensitivity was enhanced by 4 days metformin treatment, that is reduced fasting plasma insulin and HOMA-IR. In conclusion, acute and short-term metformin treatment does not affect energy homeostasis and AMPK activation at rest or during exercise in skeletal muscle and adipose tissue of healthy subjects. However, metformin treatment is accompanied by slightly enhanced perceived exertion and whole-body stress which may provoke a lesser desire for physical activity in the metformin-treated patients.

U2 - 10.14814/phy2.14307

DO - 10.14814/phy2.14307

M3 - Journal article

C2 - 31833226

VL - 7

SP - 1

EP - 17

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 23

M1 - e14307

ER -

ID: 58646299